Title |
Have the Findings from Clinical Risk Prediction and Trials Any Key Messages for Safety Pharmacology?
|
---|---|
Published in |
Frontiers in Physiology, November 2017
|
DOI | 10.3389/fphys.2017.00890 |
Pubmed ID | |
Authors |
Jem D. Lane, Andrew Tinker |
Abstract |
Anti-arrhythmic drugs are a mainstay in the management of symptoms related to arrhythmias, and are adjuncts in prevention and treatment of life-threatening ventricular arrhythmias. However, they also have the potential for pro-arrhythmia and thus the prediction of arrhythmia predisposition and drug response are critical issues. Clinical trials are the latter stages in the safety testing and efficacy process prior to market release, and as such serve as a critical safeguard. In this review, we look at some of the lessons to be learned from approaches to arrhythmia prediction in patients, clinical trials of drugs used in the treatment of arrhythmias, and the implications for the design of pre-clinical safety pharmacology testing. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 26 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 5 | 19% |
Student > Master | 5 | 19% |
Researcher | 3 | 12% |
Librarian | 1 | 4% |
Student > Bachelor | 1 | 4% |
Other | 0 | 0% |
Unknown | 11 | 42% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 5 | 19% |
Medicine and Dentistry | 3 | 12% |
Agricultural and Biological Sciences | 2 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
Nursing and Health Professions | 1 | 4% |
Other | 2 | 8% |
Unknown | 12 | 46% |